Syntimmune (Series A)
Funding Details
- Awarder
- Inbox
- Date Award
- March 22, 2016
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
- Funding Amount:
- $10,000,000
Company Info
- Founding Year
- 2013
- Founders
- Laurence Blumberg, M.D.
- Company Description
- Founded in 2013, Syntimmune is advancing novel therapies based on its leading position in the biology of the neonatal Fc receptor (FcRn). The company is developing SYNT001, a biologic that blocks the FcRn-IgG interaction for the treatment of IgG-mediated autoimmune diseases.
- Market
- IgG-mediated autoimmune diseases
- Location
- New York, New York, USA
- Coinvestors
- Apple Tree Partners, Baxalta Ventures